Liquidia Loses About Half Its Value After Court Finds Yutrepia Infringes Two United Therapeutics Patent Claims

SentiSense · Published · Updated

A federal court in Delaware ruled on September 30, 2026 that Liquidia's inhaled treprostinil Yutrepia infringes claims 1 and 14 of United Therapeutics...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis